Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus guselkumabista, jota annettiin ihon alle bionaiiveille osallistujille, joilla on aktiivinen nivelpsoriaattinen aksiaalinen sairaus (STAR)

maanantai 2. marraskuuta 2026 päivittänyt: Janssen Research & Development, LLC

Vaihe 4, monikeskus, satunnaistettu, kaksoissokkoutettu, lumekontrolloitu tutkimus, jossa arvioitiin ihonalaisesti annetun guselkumabin tehoa ja turvallisuutta bionaiiveille osallistujille, joilla on aktiivinen nivelpsoriaasi aksiaalinen sairaus

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Tutkimuksen yleiskatsaus

Tila

Aktiivinen, ei rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 protein subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23-mediated intracellular signaling, activation, and cytokine production. This study will consist of a screening phase (up to 6 weeks), a treatment phase (up to 48 weeks, including a placebo-controlled period from Week 0 to Week 24 and an active-controlled treatment phase from Week 24 to Week 48), and a safety follow-up phase (up to Week 60). The efficacy assessments will include assessment such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and the safety assessments will include evaluations of physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and adverse events. The overall duration of the study will be up to 14 months.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

411

Vaihe

  • Vaihe 4

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Buenos Aires, Argentiina, C1199ABB
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentiina, C1417
        • Centro Privado de Medicina Familiar
      • Buenos Aires, Argentiina, 1428
        • Cosultorios Reumatologógicos Pampa
      • La Plata, Argentiina, B1900
        • Hospital Italiano La Plata
      • San Fernando, Argentiina, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, Argentiina, T4000AXL
        • Centro Medico Privado de Reumatologia
      • Camberwell, Australia, 3124
        • Emeritus Research
      • Hobart, Australia, 7000
        • Southern Clinical Research
      • Liverpool, Australia, 2170
        • Liverpool Hospital
      • Maroochydore, Australia, 4558
        • Rheumatology Research Unit
      • Melbourne, Australia, 3128
        • Eastern Health - Box Hill Hospital
      • Melbourne, Australia, 3053
        • Skin Health Institute Inc.
      • Pleven, Bulgaria, 5804
        • UMHAT 'Dr. Georgi Stranski', EAD
      • Pleven, Bulgaria, 5803
        • Exacta Medica
      • Plovdiv, Bulgaria, 4001
        • UMHAT Kaspela
      • Plovdiv, Bulgaria, 4001
        • Medical Center Unimed Plovdiv
      • Plovdiv, Bulgaria, 4002
        • Medical Center Artmed
      • Sofia, Bulgaria, 1606
        • Military Medical Academy
      • Sofia, Bulgaria, 1680
        • DCC Convex EOOD
      • Sofia, Bulgaria, 1794
        • Medical Centre Synexus
      • Sofia, Bulgaria, 1336
        • MHAT 'Lyulin' EAD
      • Sofia, Bulgaria, 1612
        • UMHAT St. Ivan Rilski
      • Sofia, Bulgaria, 1750
        • ASIMP Rheumatology Centre St Irina EOOD
      • Sofia, Bulgaria, 1336
        • University Multiprofile Hospital Sofiamed Sofia
      • Targovishte, Bulgaria, 7700
        • DDC Sv. Ivan Rilski OOD
      • A Coruña, Espanja, 15006
        • Hosp Univ A Coruna
      • Barakaldo, Espanja, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, Espanja, 08036
        • Hosp Clinic de Barcelona
      • Bilbao, Espanja, 48013
        • Hosp. Univ. de Basurto
      • Córdoba, Espanja, 14004
        • Hosp Reina Sofia
      • Madrid, Espanja, 28040
        • Hosp. Clinico San Carlos
      • Málaga, Espanja, 29009
        • Hosp Regional Univ de Malaga
      • Sabadell, Espanja, 8208
        • Corporacio Sanitari Parc Tauli
      • Santiago de Compostela, Espanja, 15702
        • Clinica Gaias
      • Seville, Espanja, 41009
        • Hosp. Virgen Macarena
      • Seville, Espanja, 41013
        • Hosp. Quiron Sagrado Corazon
      • Valencia, Espanja, 46026
        • Hosp. Univ. I Politecni La Fe
      • Cebu City, Filippiinit, 6000
        • Cebu Doctors' University Hospital
      • Davao City, Filippiinit, 8000
        • Davao Doctors Hospital
      • Lipa, Filippiinit, 4217
        • Lipa Medix Medical Hospital
      • Manila, Filippiinit, 1000
        • Philippine General Hospital
      • Manila, Filippiinit, 1000
        • ManilaMed Medical Center Manila
      • Quezon City, Filippiinit, 1112
        • St. Luke's Medical Center
      • San Fernando City, Filippiinit, 2500
        • Ilocos Training and Regional Medical Center
      • Batumi, Georgia, 6010
        • Ltd Health Center
      • Kutaisi, Georgia, 4600
        • LTD Clinic LJ
      • Tbilisi, Georgia, 0112
        • LTD Helsicore
      • Tbilisi, Georgia, 0102
        • Aleksandre Aladashvili Clinic LLC
      • Tbilisi, Georgia, 0141
        • TSMU The First University Clinic
      • Tbilisi, Georgia, 0179
        • Clinic on Mtskheta Street
      • Tbilisi, Georgia, 0186
        • Consilium Medulla-multiprofile clinic Ltd
      • Tbilisi, Georgia, 0160
        • LTD MediClub Georgia
      • Tbilisi, Georgia, 0180
        • LTD The First Medical Center
      • Tbilisi, Georgia, 0160
        • LTD 'Aversi Clinic'
      • Tbilisi, Georgia, 0102
        • Ltd American Hospital Network
      • Tbilisi, Georgia, 0159
        • JSC K Eristavi National Center of experimental and Clinical surgery
      • Tbilisi, Georgia, 0159
        • Tbilisi Heart and Vascular Clinic Ltd
      • Tbilisi, Georgia, 0114
        • Ltd New Hospitals
      • Tnilisi, Georgia, 0159
        • JSC Evex Hospitals
      • Hong Kong, Hong Kong
        • Prince Of Wales Hospital
      • Haifa, Israel, 31048
        • Bnai Zion Medical Center
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Holon, Israel, 5822012
        • Wolfson Medical Center
      • Kfar Saba, Israel, 4428164
        • Meir Medical Center
      • Ramat Gan, Israel, 5265601
        • Sheba Medical Center
      • Ancona, Italia, 60126
        • A.O. Universitaria Ospedali Riuniti di Ancona
      • Monserrato, Italia, 09124
        • Azienda Ospedaliero-Universitaria di Cagliari
      • Reggio Emilia, Italia, 42123
        • Arcispedale Santa Maria Nuova - IRCCS
      • Roma, Italia, 00133
        • Policlinico Tor Vergata
      • Rozzano (MI), Italia, 20089
        • Humanitas Hospital
      • Verona, Italia, 37126
        • Azienda Ospedaliera Universitaria Integrata Verona
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 4E8
        • Skin Care Centre
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1C 5B8
        • Eastern Regional Health Authority St Clares Mercy Hospital
    • Ontario
      • Toronto, Ontario, Kanada, M5T 2S8
        • Toronto Western Hospital
    • Quebec
      • Québec, Quebec, Kanada, G1V 3M7
        • G R M O Groupe de recherche en maladies osseuses Inc
      • Batu Caves, Malesia, 68100
        • Hospital Selayang
      • George Town, Malesia, 10990
        • Hospital Pulau Pinang
      • Johor Bahru, Malesia, 81100
        • Hospital Sultan Ismail
      • Kuala Lumpur, Malesia, 59100
        • University Malaya Medical Centre
      • Seremban, Malesia, 70300
        • Hospital Tuanku Jaafar
      • Braga, Portugali, 4710-243
        • Uls Braga - Hosp. Braga
      • Guarda, Portugali, 6300-749
        • Ulsg - Hosp. Sousa Martins
      • Lisbon, Portugali, 1350-352
        • Hosp. Cuf Tejo
      • Lisbon, Portugali, 1649-035
        • Uls Santa Maria - Hosp. Santa Maria
      • Lisbon, Portugali, 1050 034
        • Ipr Inst Port de Reumatologia
      • Lisbon, Portugali, 1349-019
        • Uls Lisboa Ocidental - Hosp. Egas Moniz
      • Ponte de Lima, Portugali, 4990-041
        • Ulsam - Hosp. Conde de Bertiandos
      • Porto, Portugali, 4200 319
        • Uls Sao Joao - Hosp. Sao Joao
      • Bialystok, Puola, 15 879
        • ClinicMed Daniluk Nowak Spolka Komandytowa
      • Bydgoszcz, Puola, 85 168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela
      • Bytom, Puola, 41 902
        • Nzoz Bif Med
      • Elblag, Puola, 82-300
        • Centrum Kliniczno Badawcze
      • Elblag, Puola, 82-300
        • Ambulatorium sp. z o.o.
      • Krakow, Puola, 30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Krakow, Puola, 31-513
        • Centrum Medyczne Promed
      • Lodz, Puola, 90-338
        • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
      • Lodz, Puola, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Lodz, Puola, 91 363
        • Centrum Medyczne AMED oddzial w Lodzi
      • Lublin, Puola, 20 607
        • Reumed Zespol Poradni Specjalistycznych Filia nr 1
      • Lublin, Puola, 20-412
        • Pro Life Medica Sp. z o.o.
      • Lublin, Puola, 20 831
        • Velocity Lublin
      • Nadarzyn, Puola, 05-830
        • NZOZ Lecznica MAK MED S C
      • Nowa Sól, Puola, 67-100
        • Twoja Przychodnia - Centrum Medyczne Nowa Sol
      • Poznan, Puola, 60 324
        • Twoja Przychodnia PCM
      • Poznan, Puola, 60-446
        • Reumedika s c Wieslawa Porawska Lukasz Porawski
      • Torun, Puola, 87-100
        • MICS Centrum Medyczne Torun
      • Warsaw, Puola, 02-793
        • ETG Warszawa
      • Warsaw, Puola, 00-874
        • MICS Centrum Medyczne Warszawa
      • Warsaw, Puola, 02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw, Puola, 02-665
        • Centrum Medyczne Reuma Park
      • Warsaw, Puola, 02 118
        • Rheuma Medicus Sp z o o
      • Warsaw, Puola, 03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw, Puola, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Świdnik, Puola, 21 040
        • Lubelskie Centrum Diagnostyczne
      • Solna, Ruotsi, 171 76
        • Karolinska Universitetssjukhuset
      • Uppsala, Ruotsi, 753 09
        • Akademiska Sjukhuset
      • Berlin, Saksa, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Hamburg, Saksa, 20095
        • Hamburger Rheuma Forschungszentrum II
      • Herne, Saksa, 44649
        • Rheumazentrum Ruhrgebiet
      • Ratingen, Saksa, 40878
        • Rheumazentrum Ratingen
      • Martin, Slovakia, 036 01
        • Reumatologicka Ambulancia 1
      • Nové Mesto nad Váhom, Slovakia, 91501
        • Reumatologicka ambulancia
      • Piešťany, Slovakia, 921 01
        • Reumatologická ambulancia Thermium s.r.o.
      • Poprad, Slovakia, 05801
        • REUMAMED POPRAD, s.r.o.
      • Rimavská Sobota, Slovakia
        • Reumex s.r.o
      • Hsinchu, Taiwan, 30059
        • National Taiwan University Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Taoyuan, Taiwan, 33305
        • Linkou Chang Gung Memorial Hospital
      • Frederiksberg, Tanska, 2000
        • Frederiksberg Hospital
      • Glostrup Municipality, Tanska, 2600
        • Rigshospitalet Glostrup
      • Køge, Tanska, 4600
        • Køge Sygehus Region Sjaelland
      • Vejle, Tanska, 7100
        • Vejle Sygehus
      • Bangkok, Thaimaa, 10400
        • Phramongkutklao Hospital and Medical College
      • Bangkok, Thaimaa, 10400
        • Ramathibodi Hospital Mahidol University
      • Chiang Mai, Thaimaa, 50200
        • Chiang Mai University
      • Adana, Turkki (Türkiye), 01370
        • Adana City Hospital
      • Ankara, Turkki (Türkiye), 06800
        • Ankara Bilkent City Hospital
      • Ankara, Turkki (Türkiye), 6100
        • Hacettepe University Medical Faculty
      • Ankara, Turkki (Türkiye), 06010
        • Gulhane Training and Research Hospital
      • Antalya, Turkki (Türkiye), 7059
        • Akdeniz University Medical Faculty
      • Bursa, Turkki (Türkiye), 16059
        • Uludag University Medical Faculty
      • Istanbul, Turkki (Türkiye), 34098
        • Istanbul University Cerrahpasa Medical Faculty
      • Istanbul, Turkki (Türkiye), 34899
        • Marmara University Medical Faculty
      • Konya, Turkki (Türkiye), 42080
        • Necmettin Erbakan University Meram Medical Faculty
      • Brno, Tšekki, 61141
        • Revmaclinic
      • Brno, Tšekki, 63800
        • Revmatologie s r o
      • Brno-Židenice, Tšekki, 615 00
        • Revmacentrum MUDr Mostera s r o
      • Hlučín, Tšekki, 748 01
        • L K N Arthrocentrum
      • Karvina Frystat, Tšekki, 73301
        • Revimex Pro s r o
      • Ostrava, Tšekki, 70800
        • MUDr Rosypalova s r o
      • Pardubice, Tšekki, 53002
        • Arthrohelp S.R.O.
      • Prague, Tšekki, 128 00
        • Revmatologicky ustav
      • Uherské Hradiště, Tšekki, 68601
        • Medical Plus S R O
      • Cherkasy, Ukraina, 18009
        • Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council
      • Kharkiv, Ukraina, 61204
        • Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital
      • Khmelnytsky, Ukraina, 29000
        • Khmelnitckiy regional hospital
      • Kryvyi Rih, Ukraina, 50056
        • City Clinical Hospital No. 2
      • Kyiv, Ukraina, 03049
        • Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
      • Kyiv, Ukraina, 03680
        • SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine
      • Kyiv, Ukraina, 02081
        • Medical Center of 'Institute of Rheumatology', LLC
      • Lutsk, Ukraina, 43005
        • Volyn Regional Clinical Hospital
      • Odesa, Ukraina, 65025
        • Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
      • Poltava, Ukraina, 36011
        • ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
      • Ternopil, Ukraina, 46002
        • Municipal institution of Tepnopil Regional Council 'Ternopil University Hospital'
      • Vinnytsia, Ukraina, 21009
        • Health Clinic Limited Liability Company
      • Zaporizhzhya, Ukraina, 69600
        • Medical Center LLC 'Modern Clinic'
      • Budapest, Unkari, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, Unkari, 1023
        • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
      • Budapest, Unkari, H-1036
        • Qualiclinic Kft
      • Gyula, Unkari, 5700
        • Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
      • Hódmezővásárhely, Unkari, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kistarcsa, Unkari, 2143
        • Kistarcsai Flor Ferenc Korhaz
      • Székesfehérvár, Unkari, 8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Veszprém, Unkari, 8200
        • Vital Medical Center Orvosi es Fogaszati Kozpont
      • Barnaul, Venäjä, 656038
        • Altay Medical State University
      • Chelyabinsk, Venäjä, 454076
        • Chelyabinck Regional Clinical Hospital
      • Chelyabinsk, Venäjä, 454092
        • Chelyabinsk Regional Clinical Dermatovenerological Dispensary
      • Izhevsk, Venäjä, 426009
        • Regional Clinical Diagnostic Center of Udmurtia Region
      • Kemerovo, Venäjä, 650070
        • LLL Medical Center Revma-Med
      • Korolyov, Venäjä, 141060
        • LLC Family Outpatient Clinic # 4
      • Krasnoyarsk, Venäjä, 660123
        • Regional SBI of PH Krasnoyarsk Regional Clinical hospital #20 named after I.S. Berzon
      • Moscow, Venäjä, 115419
        • Clinical-Diagnostic Center Euromedservice, JSC
      • Moscow, Venäjä, 115522
        • FGBU Research Institute of Rheumatology named V.A.Nasonova
      • Moscow, Venäjä, 129110
        • GBUZ of Moscow Region 'Moscow Region SRI n.a. Vladimirskyi'
      • Omsk, Venäjä, 644024
        • Llc Ultramed
      • Orenburg, Venäjä, 460000
        • GBOU VPO Orenburg State Medical University
      • Perm, Venäjä, 614990
        • GBUZ Perm Regional Clinical Hospital
      • Petrozavodsk, Venäjä, 185019
        • Republican Hospital n.a.V.A.Baranov
      • Rostov-on-Don, Venäjä, 344007
        • Rostov Regional Clinical Dermatovenerological Dispensary
      • Saint Petersburg, Venäjä, 190068
        • St. Petersburg GBUZ Clinical Reumatological Hospital 25
      • Saint Petersburg, Venäjä, 194156
        • X7 Clinical Research Company Limited
      • Tolyatti, Venäjä, 445846
        • GBUZ of Samara Region 'Tolyatti City Clinical Hospital 5'
      • Ufa, Venäjä, 450005
        • Republican Clinical Hospital - G.G. Kuvatov
      • Yaroslavl, Venäjä, 150007
        • Clinical Hospital #3
      • Yekaterinburg, Venäjä, 620102
        • Sverdlovsk Regional Clinical Hospital N. 1
      • Barnet, Yhdistynyt kuningaskunta, EN5 3DJ
        • Royal Free London NHS Foundation Trust
      • Bradford, Yhdistynyt kuningaskunta, BD5 0NA
        • St. Lukes Hospital
      • Coventry, Yhdistynyt kuningaskunta, CV2 2DX
        • University Hospital Coventry & Warwickshire NHS Trust
      • Leeds, Yhdistynyt kuningaskunta, LS7 4SA
        • Chapel Allerton Hospital
      • Manchester, Yhdistynyt kuningaskunta, M13 9WL
        • Central Manchester University Hospitals NHS Foundation Trust
      • Newcastle, Yhdistynyt kuningaskunta, NE29 8NH
        • North Tyneside General Hospital
      • Stoke-on-Trent, Yhdistynyt kuningaskunta, ST6 7AG
        • Haywood Hospital
    • Arizona
      • Avondale, Arizona, Yhdysvallat, 85392
        • Arizona Arthritis and Rheumatology Research PLLC 1
      • Chandler, Arizona, Yhdysvallat, 85225
        • Arizona Arthritis & Rheumatology Research, PLLC
      • Mesa, Arizona, Yhdysvallat, 85210
        • Arizona Arthritis and Rheumatology Research PLLC
      • Phoenix, Arizona, Yhdysvallat, 85032
        • Arizona Arthritis Research, PLC.
      • Sun City, Arizona, Yhdysvallat, 85351
        • Arizona Arthritis and Rheumatology Associates
      • Tucson, Arizona, Yhdysvallat, 85723
        • Southern Arizona VA Healthcare System
    • Arkansas
      • Searcy, Arkansas, Yhdysvallat, 72143
        • Unity Health-White County Medical Center
    • California
      • Fontana, California, Yhdysvallat, 92335
        • Kaiser Permanent Medical Center
      • Huntington Beach, California, Yhdysvallat, 92648
        • Newport Huntington Medical Group
      • La Jolla, California, Yhdysvallat, 92093
        • University Of California San Diego
      • San Diego, California, Yhdysvallat, 92128
        • Rheumatology Center of San Diego
    • Connecticut
      • Danbury, Connecticut, Yhdysvallat, 06810
        • Clinical Research Center of Connecticut
    • Florida
      • Bay Pines, Florida, Yhdysvallat, 33744
        • Bay Pines VA Healthcare System
      • Plantation, Florida, Yhdysvallat, 33324
        • Integral Rheumatology And Immunology Specialists
      • Zephyrhills, Florida, Yhdysvallat, 33542
        • Florida Medical Clinic, P.A.
    • Illinois
      • Chicago, Illinois, Yhdysvallat, 60640
        • Great Lakes Clinical Trials
      • Rockford, Illinois, Yhdysvallat, 61114
        • OrthoIllinois
      • Willowbrook, Illinois, Yhdysvallat, 60527
        • Willow Rheumatology and Wellness
    • Maryland
      • Baltimore, Maryland, Yhdysvallat, 21224
        • Johns Hopkins Bayview Medical
      • Hagerstown, Maryland, Yhdysvallat, 21740
        • Klein And Associates M D P A
    • Michigan
      • Saint Clair Shores, Michigan, Yhdysvallat, 48081
        • Clinical Research Institute of Michigan, LLC
    • Minnesota
      • Eagan, Minnesota, Yhdysvallat, 55121
        • St. Paul Rheumatology P A
    • Missouri
      • Kansas City, Missouri, Yhdysvallat, 64111
        • Kansas City Physician Partners
      • Springfield, Missouri, Yhdysvallat, 65807
        • Clinvest
    • Ohio
      • Vandalia, Ohio, Yhdysvallat, 45377
        • STAT Research, Inc.
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239
        • OHSU Rheumatology Clinic, Marquam Hill
    • Texas
      • Amarillo, Texas, Yhdysvallat, 79124
        • Amarillo Center for Clinical Research
      • Austin, Texas, Yhdysvallat, 78731
        • Austin Regional Clinic
      • Colleyville, Texas, Yhdysvallat, 76034
        • Precision Comprehensive Clinical Research Solutions
      • Corpus Christi, Texas, Yhdysvallat, 78404
        • Adriana Pop Moody MD Clinic PA
      • Fort Worth, Texas, Yhdysvallat, 76109
        • AARA Clinical Research Lone Star Arthritis and Rheumatology 1
      • Houston, Texas, Yhdysvallat, 77030
        • UT Physicians Center for Autoimmunity
      • Irving, Texas, Yhdysvallat, 75039
        • AARA Clinical Research Lone Star Arthritis and Rheumatology
      • Lubbock, Texas, Yhdysvallat, 79424
        • West Texas Clinical Research
      • Mesquite, Texas, Yhdysvallat, 75150
        • Southwest Rheumatology Research LLC
      • Red Oak, Texas, Yhdysvallat, 75154
        • Epic Medical Research
      • Tomball, Texas, Yhdysvallat, 77375
        • DM Clinical Research
    • Washington
      • Seattle, Washington, Yhdysvallat, 98104
        • Swedish Medical Center

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months prior to the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) criteria at screening
  • Have active PsA as defined by: a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline and b) C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram/deciliter (mg/dL) at screening from the central laboratory, and despite previous non-biologic disease modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
  • Have magnetic resonance imaging (MRI)-confirmed PsA axial disease (positive MRI spine and/or sacroiliac [SI] joints, shown by a Spondyloarthritis Research Consortium of Canada [SPARCC] score of >= 3 in either the spine or the sacroiliac joints)
  • Have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4, and have a spinal pain score (on a visual analog scale [VAS]) of at least 4
  • Have active plaque psoriasis, with at least 1 psoriatic plaque of >= 2 centimeter (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis

Exclusion Criteria:

  • Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients
  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), ankylosing spondylitis (AS)/non-radiographic-axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has previously received any biologic treatment
  • Has ever received a Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor
  • Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Group 1: Guselkumab and Placebo

Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.

Guselkumab will be administered as subcutaneous injection.

Muut nimet:
  • TREMFYA

Matching placebo will be administered as subcutaneous injection.

Kokeellinen: Group 2: Guselkumab

Participants will receive guselkumab SC.

Guselkumab will be administered as subcutaneous injection.

Muut nimet:
  • TREMFYA
Kokeellinen: Group 3: Placebo followed by Guselkumab

Participants will receive matching placebo and will cross over to receive guselkumab SC.

Guselkumab will be administered as subcutaneous injection.

Muut nimet:
  • TREMFYA

Matching placebo will be administered as subcutaneous injection.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 24
Aikaikkuna: Baseline and Week 24

BASDAI is a self-assessment tool that consists of 6 questions relating to 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. First 5 items were scored on a 10 centimeter (cm) visual analog scale (VAS) ranging from 0 equals to (=) none to 10=very severe. Quantitative morning stiffness was scored on a 10 cm VAS ranging from 0=0 hours to 10=2 or more hours. 2 scores for qualitative and quantitative morning stiffness were averaged, and total BASDAI score was average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity.

Baseline and Week 24

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change from Baseline in Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP) at Week 24
Aikaikkuna: Baseline and Week 24

The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the C-reactive protein (CRP) value. Selected cut-offs for improvement scores are: a change greater than or equal to (>=) 1.1 units for "clinically important improvement" and a change >= 2.0 units for "major improvement.

Baseline and Week 24
Change from Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 24
Aikaikkuna: Baseline and Week 24

DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (milligram/deciliter [mg/dL], value less than [<] lower limit of quantification [LLOQ] is considered equal to half of the value of LLOQ for numerical calculations), participant assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Baseline and Week 24
Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24
Aikaikkuna: Baseline and Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Baseline and Week 24
Percentage of Participants with Investigator's Global Assessment (IGA) 0/1 Response at Week 24 among Participants with >= 3% Body Surface Area (BSA) Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Aikaikkuna: Week 24

Percentage of participants with IGA 0/1 response at week 24 among the participants with >= 3 percent (%) BSA psoriatic involvement and an IGA score of >= 2 (mild) at baseline will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given timepoint. Overall lesions are graded for induration, erythema, and scaling using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 24
Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Score for Magnetic Resonance Imaging (MRI) Sacroiliac (SI) Joints at Week 24
Aikaikkuna: Baseline and Week 24

Change from baseline in SPARCC score for MRI SI joints at week 24 among the participants with a positive MRI of the sacroiliac joints at baseline will be reported. SPARCC method focuses on the cartilaginous portion of the SI joint, and scores presence (score of 1) versus absence (score of 0) of bone marrow edema in each SI joint quadrant.

Baseline and Week 24
Percentage of Participants who Achieve a >= 50 % Improvement from Baseline in BASDAI Score at Week 24
Aikaikkuna: Baseline and Week 24

Percentage of participants who achieve a >= 50 % improvement from baseline in BASDAI score at week 24 will be reported.

Baseline and Week 24
Percentage of Participants who Achieve ASDAS Clinically Important Improvement at Week 24
Aikaikkuna: Week 24

Percentage of participants who achieve ASDAS clinically important improvement at week 24 will be reported.

Week 24
Percentage of Participants who Achieve Ankylosing Spondylitis Activity Score (ASAS) 40 Response at Week 24
Aikaikkuna: Week 24

Percentage of participants who achieve ASAS 40 response at Week 24 will be reported. ASAS 40 defined as improvement from baseline of >= 40% and with an absolute improvement from baseline of at least 2 on 0 to 10 cm scale in at least 3 of following 4 domains: Participant's global assessment (0 to 10 cm; 0=very well, 10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10 cm; 0=none, 10=very severe); no worsening at all from baseline in remaining domain.

Week 24
Percentage of Participants who Achieve ASDAS Major Improvement at Week 24
Aikaikkuna: Week 24

Percentage of participants who achieve ASDAS major improvement at Week 24 will be reported.

Week 24
Change from Baseline in SPARCC Score for MRI Spine at Week 24
Aikaikkuna: Baseline and Week 24

Change from baseline in SPARCC score for MRI spine at week 24 among the participants with a positive MRI of the spine at baseline will be reported. The SPARCC scoring system for the spine scores the 6 discovertebral units considered by the reader as the most abnormal, and then separately assesses each quadrant of 3 adjacent sagittal slices, with additional points for "depth" and high "intensity" of the lesion.

Baseline and Week 24
Number of Participants with Adverse Events (AEs)
Aikaikkuna: Up to 60 weeks

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 60 weeks
Number of Participants with Serious Adverse Events (SAEs)
Aikaikkuna: Up to 60 weeks

A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

Up to 60 weeks
Number of Participants with Reasonably Related AEs
Aikaikkuna: Up to 60 weeks

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 60 weeks
Number of Participants with AEs Leading to Discontinuation of Study Intervention
Aikaikkuna: Up to 60 weeks

Number of participants with AEs leading to discontinuation of study intervention will be reported.

Up to 60 weeks
Number of Participants with Infections
Aikaikkuna: Up to 60 weeks

Number of participants with infections will be reported.

Up to 60 weeks
Number of participants with Injection-Site Reactions
Aikaikkuna: Up to 60 weeks

Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site.

Up to 60 weeks
Number of Participants with Laboratory Abnormalities (Chemistry, Hematology) by Maximum Toxicity (Common Terminology Criteria for Adverse Events [CTCAE 5.0]) Grades
Aikaikkuna: Up to 60 weeks

Number of participants with laboratory abnormalities (chemistry, hematology) by maximum toxicity (CTCAE 5.0) grades will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.

Up to 60 weeks
Serum Guselkumab Concentration Over Time
Aikaikkuna: Up to 60 weeks

Serum guselkumab concentration over time will be reported.

Up to 60 weeks
Number of Participants with Antibodies to Guselkumab
Aikaikkuna: Up to 60 weeks

Number of participants with antibodies to guselkumab will be reported.

Up to 60 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 30. elokuuta 2021

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. huhtikuuta 2027

Opintojen valmistuminen (Arvioitu)

Tiistai 13. huhtikuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 11. kesäkuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 11. kesäkuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Perjantai 18. kesäkuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 3. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • CR109043
  • 2021-000465-32 (EudraCT-numero)
  • CNTO1959PSA4002 (Muu tunniste: Janssen Research & Development, LLC)
  • 2023-504716-15-00 (Rekisterin tunniste: EUCT number)
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .